Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the …
Over the last 12 months, insiders at Bluejay Diagnostics, Inc. have bought $0 and sold $0 worth of Bluejay Diagnostics, Inc. stock.
On average, over the past 5 years, insiders at Bluejay Diagnostics, Inc. have bought $92,359 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500 shares for transaction amount of $1,635 was made by Dey Indranil (President and CEO) on 2023‑12‑13.
2023-12-13 | President and CEO | 500 0.044% | $3.27 | $1,635 | -85.64% | |||
2023-12-13 | director | 500 0.0413% | $3.07 | $1,535 | -85.64% | |||
2023-03-28 | President and CEO | 2,000 0.0105% | $0.44 | $880 | -49.65% | |||
2023-03-27 | President and CEO | 8,000 0.0393% | $0.44 | $3,520 | -53.01% | |||
2023-03-24 | director | 10,000 0.0502% | $0.44 | $4,400 | -51.67% | |||
2022-08-26 | Chief Financial Officer | 20,000 0.0992% | $1.03 | $20,600 | -57.23% | |||
2022-04-25 | Chief Financial Officer | 20,000 0.0943% | $0.99 | $19,800 | -21.74% | |||
2022-03-17 | 40,000 0.1983% | $1.18 | $47,120 | -24.35% | ||||
2022-03-17 | Chief Financial Officer | 2,500 0.0122% | $1.16 | $2,898 | -24.35% | |||
2022-03-17 | 10,000 0.0498% | $1.18 | $11,830 | -24.35% | ||||
2022-03-16 | 60,000 0.2823% | $1.09 | $65,400 | -20.91% | ||||
2022-03-14 | Chief Financial Officer | 5,000 0.0274% | $1.02 | $5,100 | +1.69% |